Survey finds that 1 in 8 adults have tried GLP-1 medications such as Ozempic

The use of GLP-1 drugs for weight loss and diabetes management is on the rise, with around 1 in 8 adults in the U.S. having used these medications at some point. A recent survey from KFF revealed that roughly half of those adults, or about 6% of the U.S. population, are currently using GLP-1 drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

Despite intermittent shortages caused by high demand, these treatments have become increasingly popular in the past year. Many adults reported using GLP-1 drugs to manage chronic conditions such as diabetes or heart disease, with some using them specifically for weight loss.

The survey also showed disparities in GLP-1 usage based on race and ethnicity, with higher rates among Black and Hispanic adults compared to white adults. Additionally, adults aged 50 to 64 were more likely to have used GLP-1 drugs, while younger adults were more likely to use them for weight loss.

While Medicare currently does not cover prescription weight loss drugs, a majority of adults believe it should cover these costs for overweight individuals. Many adults with health insurance reported partial or full coverage for GLP-1 drugs, highlighting the importance of insurance coverage for these expensive medications.

As GLP-1 drugs gain approval for additional health benefits, such as treating sleep apnea and fatty liver disease, the demand for these medications is likely to increase. Stay tuned for more updates on the evolving landscape of GLP-1 drug usage.

In other healthcare news, Google DeepMind announced a groundbreaking AI model called AlphaFold 3, which can predict the structures of molecules with unprecedented accuracy. This technology has the potential to revolutionize drug discovery and biological research, offering new insights into complex molecular interactions.

Researchers can access the majority of AlphaFold 3’s capabilities for free through the AlphaFold Server, demonstrating Google’s commitment to sharing the benefits of this cutting-edge technology. With the ability to predict molecular structures more accurately than existing methods, AlphaFold 3 has the potential to transform biological research and accelerate scientific discoveries.

Overall, these developments in healthcare technology and medication usage signal a promising future for the field, offering new possibilities for improving patient care and advancing scientific knowledge.

Back To Top